Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice
- PMID: 33246352
- DOI: 10.1055/a-1324-8498
Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice
Abstract
Background: The POSE-2 procedure shortens and narrows the stomach using multiple full-thickness plications in the gastric body. We studied the efficacy and safety of POSE-2 for obesity at 1 year in a real-world setting.
Methods: We reviewed the records of 75 patients who underwent POSE-2 at our unit. The primary outcome was percentage total body weight loss (%TBWL) at 1 year. Secondary outcomes were safety and durability. We used linear mixed model analysis.
Results: 46 patients completed 1 year. Mean age and body mass index (BMI) were 49.3 years (standard deviation [SD] 10.2) and 38.2 kg/m2 (SD 6.6), respectively. Technical success rate was 98.7 % (n = 74). Mean TBWL, %TBWL, and BMI decline at 1 year were 20 kg (SD 12.7), 17.8 % (SD 9.5), 7 kg/m2 (SD 4.3). Adverse events occurred in four patients. The median length of stay was 1 day. Endoscopy at 1 year in 15 patients showed intact sutures and a reduction in gastric length compared with baseline (26.9 cm [SD 5.3] vs. 35.7 cm [SD 3.5]; P < 0.001).
Conclusion: POSE-2 induced significant weight loss at 1 year. It appears to be safe, durable, and required only a short hospital stay.
Thieme. All rights reserved.
Conflict of interest statement
Gontrand Lopez Nava is a paid consultant for Apollo Endosurgery, USGI Medical, USA and Nitinotes. All other authors declare that they have no conflicts of interest.
Comment in
-
Author commentary on Gontrand Lopez Nava et al.Endoscopy. 2021 Nov;53(11):v56. doi: 10.1055/a-1345-4318. Epub 2021 Oct 26. Endoscopy. 2021. PMID: 34700355 No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
